MedTrace Logo

Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis

NCT02079649 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2015-08-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AL-53817 Ophthalmic Solution, 0.1%

DRUG

AL-78843 Ophthalmic Solution, 0.03%

DRUG

Dexamethasone Ophthalmic Suspension, 0.1%

DRUG

AL-53817 Vehicle

Inactive ingredients used for masking purposes

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Clinical Trial Manager, Pharma, GCRA · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-07-31
Completion
2014-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02079649 on ClinicalTrials.gov